Venus Concept Inc. VERO
We take great care to ensure that the data presented and summarized in this overview for Venus Concept Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VERO
View allLatest Institutional Activity in VERO
Top Purchases
Top Sells
About VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Insider Transactions at VERO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 03
2024
|
Michael Willingham Masters > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
162,896
-21.79%
|
$0
$0.53 P/Share
|
Oct 02
2024
|
Michael Willingham Masters > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
94,553
-11.23%
|
$0
$0.53 P/Share
|
Oct 01
2024
|
Michael Willingham Masters > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
140,214
-14.27%
|
$0
$0.6 P/Share
|
Sep 30
2024
|
Michael Willingham Masters > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
71,368
-6.77%
|
$0
$0.64 P/Share
|
Jun 11
2024
|
Michael Willingham Masters > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
102,717
-21.13%
|
$102,717
$1.2 P/Share
|
Jun 11
2024
|
Michael Willingham Masters > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
233,345
+32.44%
|
-
|
Jun 10
2024
|
Michael Willingham Masters > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
666,702
+50.0%
|
-
|
Jun 07
2024
|
Michael Willingham Masters > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
387,231
-86.26%
|
$387,231
$1.2 P/Share
|
Aug 11
2023
|
Michael Mandarello General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-13.52%
|
-
|
Aug 11
2023
|
Michael Mandarello General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
834
+32.6%
|
-
|
Mar 25
2023
|
Michael Mandarello General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,409
-28.85%
|
-
|
Mar 25
2023
|
Michael Mandarello General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+50.0%
|
-
|
Mar 25
2023
|
Domenic Della Penna Exec VP & General Manager |
SELL
Payment of exercise price or tax liability
|
Direct |
12,778
-7.78%
|
-
|
Mar 25
2023
|
Domenic Della Penna Exec VP & General Manager |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+18.6%
|
-
|
Mar 25
2023
|
Anna Georgiadis Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,873
-31.32%
|
-
|
Mar 25
2023
|
Anna Georgiadis Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+50.0%
|
-
|
Mar 25
2023
|
William H Mcgrail Sr. VP |
SELL
Payment of exercise price or tax liability
|
Direct |
4,717
-37.74%
|
-
|
Mar 25
2023
|
William H Mcgrail Sr. VP |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+50.0%
|
-
|
Mar 25
2023
|
Ross Portaro Exec VP & General Manager |
SELL
Payment of exercise price or tax liability
|
Direct |
11,034
-7.61%
|
-
|
Mar 25
2023
|
Ross Portaro Exec VP & General Manager |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+14.71%
|
-
|
Last 12 Months Summary
Conversion of derivative security | 900K shares |
---|
Open market or private sale | 959K shares |
---|